In this issue:
- Effects of smoking and vascular risk factors on relapse risk in MOGAD
- Comorbidities and lifestyle changes associated with the MS prodrome
- Are there any sex-specific differences in early RRMS?
- Risk of severe adverse events with different MS treatment sequences
- Impact of invisible MS symptoms on social participation
- Impact of exercise interventions in severe MS
- Time savings after transitioning from intravenous to subcutaneous ocrelizumab
- The hidden burden of bowel dysfunction in MS
- Real-world drug utilisation patterns after diagnosis of RRMS
- Pathogenesis of depression in MS
Please login below to download this issue (PDF)